Prevalence of Serous Macular Detachment in Recurrent Macular Edema Secondary to Retinal Vein Occlusion
Introduction Retinal vein occlusion (RVO) is the second most common retinal vascular disorder, and cystoid macular edema (CME) is the main cause of vision loss in these patients. 1 Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab, bevacizumab, and aflibercept) and steroids (triamcinolone acetonide and sustained-release dexamethasone implant) has been found to be effective in the treatment of macular edema secondary to RVO.
Conclusion:This study suggests that SMD seems to be more frequent in patients with recurrent CME secondary to CRVO when compared to BRVO. The choice of initial intravitreal treatment with either ranibizumab or dexamethasone implant did not affect the prevalence of SMD in recurrent CME. However, longer-term prospective studies including a larger number of patients with similar pretreatment baseline characteristics are needed to reach a more accurate and definitive conclusion.